Mechanism of action of the antitumor agents 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: potent inhibitors of human type II inosine 5'-monophosphate dehydrogenase.
The observation that expression of the IMPDH gene is tightly linked with cellular proliferation and transformation has led to an interest in developing inhibitors that deplete intracellular guanine nucleotide pools. IMPDH exists as 2 isoforms, one of which is induced in tumor cells, type II and thus has led to new interest in this target for the design of isoform-selective anticancer chemotherapeutic agents. Several classes of IMPDH inhibitor are now in use or under development; however, only the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones show selectivity for the type II isoform. In the current study, we further evaluated chemical modification of this class to determine the necessary components for selective type II IMPDH inhibition. The 6-benzoyl-3,3-disubstituted-1,5-diazabicyclo[3.1.0]hexane-2,4-diones were effective cytotoxic agents in human leukemias, lymphomas, breast, glioma and HeLa-S3 suspended uterine carcinoma screens with ED(50) values 0.3 to 12 microM. The agents acted as antimetabolites by inhibiting de novo purine biosynthesis at the key regulatory enzyme IMPDH, resulting in suppression of DNA synthesis and dGTP pool levels within 60 min. Furthermore, the derivatives were specific for the type II isoform as opposed to type I, acting in a competitive manner with K(i) values of 5.1 to 63 microM. Addition of the 6-benzoyl moiety to the bicyclic parent ring structure afforded the most potent agent in the novel class of 1,5-diazabicyclo[3.1.0]hexane-2,4-diones that selectively inhibits type II IMPDH activity.
Barnes
B J
BJ
Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. barnebe@jhmi.edu
Izydore
R A
RA
Eakin
A E
AE
Hall
I H
IH
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D007168:IMP Dehydrogenase